Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

  • Interventional
  • Not Recruiting
  • NCT02562755
Eligibility Details Visit Clinicaltrials.gov

A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.

This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed by sorafenib versus sorafenib in patients with advanced HCC without prior systemic therapy.

     A total of 600 patients will be randomly assigned to 2 treatment arms in a 1:1 ratio (300 in each arm) to reach at least 570 evaluable patients.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Histological/cytological diagnosis of primary HCC

         - Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American Association for the Study of Liver Disease [AASLD] guidelines)

         - At least one measurable viable tumor in the liver, ≥1 cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)

         - Child-Pugh Class A

         - Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale

         - Adequate hematological, hepatic, and renal function:

         - Additional inclusion criteria exist

        Exclusion Criteria:

         - Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinoma, fibrolamellar carcinoma and hepatoblastoma

         - Symptomatic cardiovascular disease, including but not limited to significant coronary artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months

         - Current or past history of cardiovascular disease (e.g.. past history of myocardial infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has been obtained for study participation

         - History of moderate or severe ascites, bleeding esophageal varices, hepatic encephalopathy or pleural effusions related to liver insufficiency within 6 months of screening

         - Bulky disease patients - tumors encompassing >50% of the liver volume and / or inferior vena cava invasion

         - Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including high-dose corticosteroids

         - Ongoing severe inflammatory skin condition (as determined by the Investigator) requiring medical treatment

         - History of severe eczema (as determined by the Investigator) requiring medical treatment

         - Additional exclusion criteria exist

At a Glance

National Government IDNCT02562755

IRB#IRB15-0976

Lead SponsorSillaJen, Inc.

Lead PhysicianChih-Yi Liao

Collaborator(s)N/A

EligibilityAll
18 Years and up
Not Recruiting